Skip to content
DataLookout
Menu

NCT04148430

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 10 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Oct 2026 to Oct 2027
    • Eligibility criteria expanded, about 5 words
    • Publications: details revised at 1 of 1 entry
  2. Notable Primary and study completion dates: Oct 2025 to Oct 2026v14
  3. Notable Primary and study completion dates: Oct 2024 to Oct 2025v12
  4. Notable Primary and study completion dates: Oct 2023 to Oct 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v10
  5. Minor Site details revised at 1 of 2 sitesv9
Show 4 earlier versionsHide 4 earlier versions
  1. Minor Study sites: 1 to 2v8
  2. Notable Enrollment target: 90 to 62
    • Eligibility criteria shortened, about 263 words
    • Study arms: 2 to 1
    v6
  3. Notable Primary and study completion dates: Oct 2022 to Oct 2023v4
  4. Notable Eligibility criteria expanded, about 272 words
    • Primary endpoints: 1 to 2
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities
Timeframe: 4 weeks
Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation
Timeframe: 28 days from the start of treatment

Arms and interventions

Arm 1 (CART Cell Group)Experimental

Cohort 1 Patients will receive anakinra 100mg s.c. every 12 hours starting on day 2 post CAR T cell infusion, or after 2 documented fevers of ≥38.5° C prior to day 2, whichever time point is earlier. Anakinra will be continued for 10 days. Cohort 2 Patients will receive anakinra 100mg s.c. daily on day 0 of T cell infusion, and continue anakinra daily for 7 days

Drugs: Anakinra

Sites

2 sites in 1 country